Today's decision by the FDA offers hope for the millions of adults living with both conditions and provides an additional treatment option, representing a significant advancement for my patients." - Richard E
Rita Kapoor help patients understand the expected timeline of semaglutide GLP-1 therapy and provide ongoing support to ensure the treatment fits each patients long-term health goals
Precio y disponibilidad pueden cambiar, especialmente en formulaciones nuevas
July 2024: A new study, published on July 3, 2024, indicates patients taking semaglutide such as Wegovy may face an increased risk of serious eye injuries, including nonarteritic anterior ischemic optic neuropathy (NAION)
Such reactions are generally mild, self-limiting, and resolve within a few days without specific intervention
The study also didnt find any adverse drug-to-drug interactions, or any impact on participants mental state